InMed’s CEO, Eric A. Adams, and BayMedica’s SVP and GM, Shane Johnson, and VP of Commercial Operations, Chris Meiering, join Tribe Public’s Webinar “Addressing the Increasing Demand for Rare Cannabinoids.”
Host John Heerdink talks to the team about which rare cannabinoids are emerging, InMed and BayMedica’s plans to launch new products to address the demand. They talk about leveraging the company’s different cannabinoid manufacturing methods to produce these rare cannabinoids and how each method will have advantages depending on the compound. They talk about the importance of being able to produce these biosynthetic rare cannabinoids at large scale – being able to take it from the “benchtop” to commercial scale, such a metric tonne quantities, if required.
In addition, they talk about how biosynthetic cannabinoid manufacturing approaches will enable access to high purity and consistent rare cannabinoids, which are impractical to extract from the plant due to their minuscule amounts in the plant.
